Cybin Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Cybin Inc. for the month of December 2025. The filing, dated December 22, 2025, and signed by Chief Financial Officer Greg Cavers, serves to disclose a news release dated December 18, 2025 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text contains only cover page and signature information. It does not include the full text of the news release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as no financial data or operational updates are included in the excerpt.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details regarding unusual items. These details would be contained within the referenced news release (Exhibit 99.1), which is not included in the input content.
Investor Verification Checklist
- Verify the full content of the news release dated December 18, 2025 (Exhibit 99.1) to understand the specific event triggering this filing.
- Confirm whether the news release contains updated financial guidance or operational milestones.
- Review the company's most recent Form 20-F or quarterly reports for the latest audited financial data, as this 6-K does not provide it.
- Check for any regulatory or clinical trial updates specific to Cybin's psychedelic medicine pipeline mentioned in the full news release.